The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
Starbucks Corporation stock (NASDAQ: SBUX) is trading slightly lower on Friday, December 19, 2025, as investors balance a “turnaround-in-progress” narrative against real-world crosscurrents: elevated coffee costs, labor disruption risk, and a still-evolving international strategy—especially in China.
As of early afternoon, Starbucks shares were $88.77, down $0.65 (-0.72%). [1]
Below is a full, up-to-the-minute look at the news flow, forecasts, and analyst views shaping SBUX today—plus the specific issues Wall Street is watching into 2026.
After a strong stretch of “green shoots” optimism around CEO Brian Niccol’s operational reset, SBUX is seeing modest profit-taking into the end of the week. The intraday dip also comes as the broader conversation around coffee prices—one of Starbucks’ most important input costs—has re-entered headlines today.
Market data trackers showed SBUX near $88.77 by early afternoon. [2]
A major macro theme for beverage and restaurant names today is the reality that retail coffee prices can remain elevated even if tariff-related pressure eases, because price transmission through the supply chain can lag by months.
In a Reuters report published today, analysts and industry sources pointed to prior supply tightness and timing lags as reasons consumer coffee prices may not quickly fall—even after recent tariff changes. [3]
This matters for Starbucks because recent company results already highlighted how commodities and related cost items can squeeze profitability. In Starbucks’ late-October earnings coverage, Reuters reported that coffee prices and tariffs were among the factors pressuring margins, alongside investment costs tied to the turnaround. [4]
Why investors care: if Starbucks stays cautious on menu price increases (to protect traffic), sustained coffee inflation can make margin recovery slower—and the stock tends to trade on the pace and credibility of that recovery.
Starbucks is in a multi-quarter effort to make stores feel less transactional and more like the brand’s original “third place,” while also improving throughput and labor deployment.
Reuters has described Niccol’s strategy as a cost-and-experience reset that he calls “Back to Starbucks.” [5]
That plan has included operational changes such as menu simplification, faster service goals, and store upgrades. [6]
Recent reporting also described Starbucks piloting new store designs and committing meaningful staffing/labor-hour investments to support execution at scale. [7]
Market takeaway: Starbucks bulls generally argue the stock can re-rate higher if “throughput + experience” improvements translate into sustainably higher transactions. Bears tend to argue it’s difficult to fix speed, service, and staffing economics simultaneously—especially with commodity and wage pressures.
Starbucks’ strategy in China has been one of the most consequential moving pieces for the equity story in 2025.
Reuters reported that Starbucks agreed to sell control of its China operations to Boyu Capital in a deal valuing the business at $4 billion, with Boyu holding up to 60% and Starbucks 40%, while Starbucks continues to license brand/IP to the venture. [8]
The same Reuters report also highlighted the competitive reality in the market, including Starbucks’ declining China market share and the rise of lower-priced competitors. [9]
Earlier in the process, Reuters also reported that bidders had valued Starbucks China as high as $5 billion, with offers often framed around an EBITDA multiple approach. [10]
What investors are debating now:
A clear near-term uncertainty for SBUX is labor disruption risk and reputational overhang.
Reuters reported on December 11 that hundreds of baristas walked off the job in 34 U.S. cities, escalating a month-long strike. The union said over 3,800 baristas had participated and that the strike had spread to more than 180 stores across 130 cities. [11]
Starbucks, in the same Reuters report, argued the impact was limited—stating that fewer than 1% of its roughly 17,000 U.S. coffeehouses had been affected at any point. [12]
On the regulatory front, New York City announced a $38.9 million settlement with Starbucks related to alleged violations of the city’s Fair Workweek Law, describing it as the largest worker-protection settlement in city history. [13]
The city said the settlement requires over $35.5 million in restitution to workers plus $3.4 million in civil penalties and costs, and applies to hourly workers in NYC across a multi-year period. [14]
Investor relevance: these items don’t necessarily change Starbucks’ long-term brand power, but they can influence risk perception, operating leverage assumptions, and how much “execution discount” the market applies to the stock.
A Reuters report on December 18 said Cuisine Solutions—known for producing Starbucks’ egg bites—hired Morgan Stanley and Rothschild to explore a potential sale process, with a valuation that could exceed $2 billion, according to sources. [15]
This isn’t a direct Starbucks corporate action, but it’s relevant in two ways:
Starbucks is also leaning into cultural collaborations as part of brand re-energizing.
Modern Retail reported this week that Starbucks hired Neiv Toledano (previously at e.l.f. Cosmetics) as a senior marketing manager of fashion and beauty, described as a first-of-its-kind dedicated role focused on partnerships/collabs. [16]
Why it matters for the stock: These initiatives are unlikely to move near-term EPS by themselves, but they speak to management’s push to rebuild relevance and traffic—especially among younger, trend-driven consumers.
Analyst communities still skew constructive on SBUX—but targets are dispersed, reflecting uncertainty about how quickly the turnaround can convert into earnings power.
StockAnalysis reports:
It also lists notable recent rating actions (examples include reiterated/maintained ratings and price-target changes from firms such as TD Cowen, Citi, RBC, and Piper Sandler across Oct–Dec). [19]
TipRanks shows:
How to interpret the spread:
When one aggregator shows a ~$95 target and another shows ~$101+, it’s usually methodology and coverage differences—not a sudden change in core sentiment. The more important signal is that targets cluster around “modest upside,” while the wide high/low range signals a market still debating Starbucks’ medium-term earnings trajectory.
The next major scheduled inflection point is earnings.
MarketBeat lists Starbucks’ upcoming Q1 earnings date as “Jan. 27 after market closes (estimated).” [21]
Separately, Reuters reporting around Starbucks’ recent results indicated the company expected to provide a financial outlook at an investor event in January (context: Starbucks suspended guidance shortly after Niccol took the helm). [22]
1. www.marketbeat.com, 2. www.marketbeat.com, 3. www.reuters.com, 4. www.reuters.com, 5. www.reuters.com, 6. www.reuters.com, 7. www.reuters.com, 8. www.reuters.com, 9. www.reuters.com, 10. www.reuters.com, 11. www.reuters.com, 12. www.reuters.com, 13. www.nyc.gov, 14. www.nyc.gov, 15. www.reuters.com, 16. www.modernretail.co, 17. www.marketbeat.com, 18. stockanalysis.com, 19. stockanalysis.com, 20. www.tipranks.com, 21. www.marketbeat.com, 22. www.reuters.com, 23. www.reuters.com, 24. www.reuters.com, 25. www.marketbeat.com, 26. www.reuters.com, 27. www.reuters.com, 28. www.nyc.gov
I’m a sucker for a good Instagram ad. Time and time again, I’m drawn in by the siren song of influencers promising me beauty, brains, or better sleep if I just buy this one thing. For the most part, these purchases are a bust — like the collagen syrup that tasted like mango-flavored hotdog water, or the overnight anti-aging body spray that gave me a neck rash (which is still lingering months later). And yet I persist, because once in a while, my pile of mail-order trash produces a treasure.
What initially drew me to Dose, apart from the sleek packaging and fact that it’s sold at LA cult-favorite store Erewhon, was the claim that one shot of this orange juice-flavored liquid is equal to 17 shots of cold-pressed turmeric. I’ve tried and failed to add turmeric supplements into my diet more times than I can count: My stomach sometimes feels “off” after meals, and I’ve heard that curcumin can make a positive impact on digestion and gut health. Unfortunately, I find the taste so off-putting that my gag reflex kicks in just from looking at one of those big orange capsules.
To be clear: Dose isn’t simply a potent serving of turmeric, it’s a daily supplement for liver support made from that beloved root and dandelion, milk thistle, and ginger. I’ll be the first to admit that before I tried it, I’d never given my liver a second thought. I’ve never had a reason to worry about it, so to me, the liver was just another enigmatic organ chugging along inside the mysterious black hole that is my body. But since I was looking for a way to up my turmeric intake, I figured I’d try it — and any additional liver support would be a bonus.
Dose does have a distinctly turmeric-y hue, so I was happily shocked by the taste: The flavor is comparable to fresh-squeezed orange juice, and it’s so refreshing that my daily shot has quickly become the best part of my morning routine.
I’ve been taking it daily for a few weeks now, and overall, I feel pretty great. That said, I take a number of other nutritional supplements, so it’s difficult to pinpoint the exact effect Dose has had on my body, besides making my mornings pleasant. So to figure out specifically what Dose does, I decided to call an expert.
Kiran Krishnan is a microbiologist with a background in research and development in molecular medicine, and he’s an expert in the dietary supplement and nutrition market. He also happens to be the liver’s number one fan. “The liver plays a crucial role in digestion, because it processes and helps eliminate unwanted elements from what we eat, drink, and breathe,” Krishnan explains. “It’s the unsung hero of our organs, but nobody talks about it unless they’re concerned about its health.”
That’s why Krishnan’s goal is to help people become more liver-conscious and support its overall health. Part of the problem, he explains, is that we truly are what we eat, and Americans aren’t eating especially well: “We’ve dramatically increased stress on the liver over the past 50 years,” he explains. “Refined sugar and drinking create stress on the liver, but trans fats are the worst — they’re highly stable, so they’re very difficult for the liver to break down.” (Signs your liver may need more support are easily confused with other health concerns — like low energy or brain fog — which signifies the importance of getting routine bloodwork done, to get a better picture of your health.)
With thousands of supplements on the market that promise to help ease your health concerns without clinical studies to back them up, you’re right to be wary as to whether some are just placebos with nice packaging. That’s what makes Dose stand out from the pack: The brand’s scientific advisory board conducted clinical research before putting the product on the market, to put customers’ minds at ease. In a placebo-controlled, double-blind study using healthy liver participants, specific liver enzyme markers were studied over the course of six months: 88 percent saw a positive impact on ALT and SLT levels and 90 percent saw a positive impact on ALP levels.
So what precisely is in a dose of Dose? It’s a group of four nutrients in highly bioavailable forms, designed for absorption: Milk thistle, dandelion, ginger, and of course, my old friend turmeric. The last plays a crucial role in the formula, supporting the body’s natural response to daily stressors: “Think of your liver like a mail room,” says Krishnan. “Everything that goes into your body gets filtered through your liver. Turmeric helps cleanse the liver of unwanted elements so it can continue to process stressors efficiently.”
Milk thistle, or silymarin, also supports liver health. “Milk thistle has been used for centuries to support the liver,” Krishnan explains. Ginger supports the liver more indirectly by aiding digestion and promoting which may ease bloating. Finally, dandelion root, which is rich in bitter compounds, activates receptors in the gut, supporting bile production. Together, these four ingredients offer complementary, non-overlapping benefits; as Krishnan puts it: “There’s a synergistic effect between each of those compounds, so combining them has an additive benefit.”
Of course, Dose isn’t for everyone, and you should ask your doctor before adding any new supplement to your diet. But if you’re looking for an easy way to support your overall health, it’s a great place to start. As an expert, Krishnan can vouch that the brand has done rigorous clinical research to show that Dose’s clinically backed formula is effective in supporting liver health. And as a consumer, I can vouch that the taste alone makes it well worth the purchase.
Caroline Pham, the acting chair of the US Commodity Futures Trading Commission (CFTC), is leaving the regulator to join the crypto payments firm MoonPay. This transition is bullish for the crypto community.
The ADA long-term outlook benefits from this stabilizing environment, but the sheer size of the Cardano network fundamentals often limits its potential for short-term gains. For retail investors looking for quick gains, the real opportunity lies in high-utility, early-stage projects.
DeepSnitch AI is an asset with such features, with its presale surging past $825,000, a confirmed January launch, and a suite of three live AI agents operational. DeepSnitch AI offers the kind of 100x potential that mature chains like Cardano can’t give anymore.
The announcement that Caroline Pham is joining MoonPay as chief legal and administrative officer is a key moment for crypto regulation. Pham, who served as acting chair of the CFTC, has been a key figure in the US financial regulatory sector.
Her move follows a trend of high-level officials taking sides in crypto. Summer Mersinger, another CFTC commissioner, recently left to lead the Blockchain Association. MoonPay confirmed the hire on December 17.
This migration of talent suggests that the “war on crypto” is ending and the “integration of crypto” has begun. For Cardano network fundamentals, this is positive news. A friendlier regulatory environment reduces the risk of securities lawsuits and encourages institutional adoption.
However, while regulation makes the market safer, it also traps the volatility that creates overnight millionaires in large-cap assets. The 100x gains are migrating further out on the risk curve to utility tokens that serve specific, high-demand niches like AI-driven trading intelligence.
While the ADA long-term outlook is built slowly, DeepSnitch AI is for speed and immediate impact. It offers something unique, which is live utility in its presale phase. DeepSnitch AI has deployed five AI agents for better trading. Although only three are currently active, the full feature is to be released at the end of the presale.
The community has staked over 20 million tokens, creating a supply scarcity that will hit right as trading begins. The team has also released the DSNTVIP100 promo code. Investors purchasing over $5,000 receive a 100% bonus, instantly doubling their token holdings. Even smaller purchases over $2,000 get a 50% boost through code DSNTVIP50.
Compared to the Cardano ADA forecast, analysts predict a 58.93% rise to reach $0.5877 by June 2026. A 58% gain over six months is decent for a savings account, but it won’t change your life. DeepSnitch AI offers the potential for 50x to 100x returns because it is starting from a low market cap with high demand and massive bonus leverage. If you want safety, buy bonds. If you want generational wealth, buy DeepSnitch AI before the presale closes.
Cardano is a top technological crypto asset. Its founder, Charles Hoskinson, recently addressed concerns about quantum computing. He dismissed the “quantum threat” as overhyped and does not pose a risk before the 2030s. This confidence in the Cardano price prediction is reassuring for holders who are in it for the next decade.
However, the current price action is discouraging. ADA is trading with “bearish” sentiment and has recorded only 11 green days since December 18. The fear & greed index is at “extreme fear” (16/100). Technical indicators show ADA struggling to break above its 50-day SMA of $0.4847.
While the network is fundamentally sound, the coin lacks immediate price moves. For investors who want to capitalize on the current market cycle, allocating capital to a slow-moving giant carries a high opportunity cost compared to the potential of DeepSnitch AI.
Avalanche has declined by 18% since December 18, underperforming the global market. The asset price predictions for late 2025 and 2026 are of concern as well. AVAX is stagnant with a loss of 5% by December 2025, and the price is at $12. The price would also not make a positive progress in 2026, with just a possible 1%.
This stagnation shows the risks of holding assets that have lost their narrative. Capital trapped in AVAX is dead money. Smart investors are cutting their losses and rotating into presales like DeepSnitch AI, where the upside potential is unrestricted, and the momentum is just beginning.
The move of top regulators into the crypto industry confirms that digital assets are here to stay. But as the market matures, the “easy gains” in large-cap coins like Cardano and Avalanche are disappearing.
The new path to wealth is through early-stage utility tokens that solve real problems, and DeepSnitch AI is the opportunity. With over $825,000 raised, a massive 100% bonus, and a live dashboard featuring powerful AI agents, DeepSnitch AI is the best buy ahead of Cardano and Avalanche.
Investors can get bonuses by applying the code DSNTVIP50 for a 50% bonus on purchases above $2,000 and DSNTVIP100 for a 100% bonus on buys over $5,000. These codes expire on January 1, and investors are advised to take advantage of this window before it’s too late.
Visit the official DeepSnitch AI website, join Telegram, and follow on X for the latest updates.
The Cardano price prediction could rise to 59%, and its price is at $0.5877. Although this is positive, growth is slower than the potential of early-stage tokens.
DeepSnitch AI offers higher upside. It is a low-cap token in its presale phase, meaning it can experience huge growth (50x 100x) much easier than a multi-billion dollar asset like Cardano.
It means that the regulatory environment is becoming friendlier and more integrated with the industry. This reduces systemic risk but also suggests a maturing market where volatility (and massive gains) in large caps will decrease, pushing investors toward presales like DeepSnitch AI.
Disclaimer: This is a Press Release provided by a third party who is responsible for the content. Please conduct your own research before taking any action based on the content.
DUBAI, United Arab Emirates, Dec. 19, 2025 (GLOBE NEWSWIRE) — As Web3 gaming and decentralized applications mature, platforms are no longer building isolated systems. They are searching for interoperable, reliable, utility-driven tokens that already possess liquidity, community trust, and real adoption. In this rapidly evolving environment, MGC has emerged as a strong candidate for broader integration across gaming, metaverse, and decentralized ecosystems.
Originally designed as the core utility token of the Ranking gaming platform, MGC has grown far beyond its initial function. With active usage, stable trading behavior, and increasing recognition on major DEXs, MGC is now positioned for the next phase of its evolution: becoming a partner-ready token that other Web3 platforms can confidently build with.
A Token Powered by Real Users and Real Activity
MGC is not a theoretical or inactive utility token, it functions inside a live gaming ecosystem. Players engage with it daily for:
Because MGC holds genuine value inside the Ranking platform, it attracts an audience that uses the token based on its function, not speculation. This real-world demand makes it appealing to external platforms seeking a token with actual behavioral data behind it.
A History of Steady, Reliable Profitability
One of the most defining characteristics of MGC, and a source of growing attention, is its historically steady and reliable profitability. While many early-stage gaming tokens experience extreme volatility, MGC has repeatedly demonstrated:
This steady track record has made MGC more than just another gaming asset; it has become a dependable store of value within its category.
Such stability inevitably strengthens loyalty among holders. Investors and ecosystem participants tend to remain committed to tokens that consistently deliver reliable performance, and MGC has built exactly that reputation.
This combination of real utility and consistent profitability has contributed to MGC’s transformation into a valuable, respected digital asset, making it an appealing choice for collaboration with other Web3 projects.
Why MGC Is Now a Strong Candidate for Cross-Ecosystem Integration
For a token to be adopted by external platforms, it must demonstrate maturity across several criteria. MGC stands out in each area.
1. A Loyal and Stable Holder Base
Because MGC has delivered dependable returns and has clear, sustainable utility, its holder base behaves more like long-term participants than short-term speculators. This stability reduces risk for platforms looking to integrate the token into their liquidity pools or reward systems.
2. Broad DEX Accessibility
MGC is available across multiple major decentralized exchanges, making it easy for partners to create liquidity pairs, open new markets, or incorporate the token into their reward mechanics without dependency on a single venue.
3. Positive Reputation and Expanding Visibility
MGC continues to appear in Web3 media through reviews, analysis videos, influencer commentary, and metaverse- or gaming-focused content. This recognition helps partner platforms integrate a token with existing awareness and community credibility.
4. Demonstrated Economic Strength
A token with reliable historical profitability, steady price behavior, and real user engagement becomes an attractive building block for:
Integrating MGC gives partner projects an asset that is already battle-tested, already trusted, and already functioning at scale.
The Road Ahead
MGC’s journey began within one gaming platform, but its future clearly extends far beyond it. With strong community loyalty, real-world utility, steady historical performance, and growing recognition across decentralized markets, MGC is now ready to participate in the next generation of Web3 partnerships.
In an industry where trust, reliability, and interoperability matter more than ever, MGC stands as a token prepared for meaningful collaboration and long-term integration across the broader Web3 ecosystem.
Friday’s closing price is on track to be the third day out of four where natural gas closed below prior support at the 200-day average, now at $3.75, and a long-term rising trendline. Daily closes below the 200-day line and trendline is bearish behavior as prior dynamic support switches to resistance. Now the 20-day average has touched the 50-day average, and it will soon cross below it, further confirming bearish sentiment.
Despite being possibly extended to the downside, bearish price action shows the potential for further downside. Given the current chart pattern, unless natural gas can rise above and then close above Thursday’s lower swing high of $3.93, downside pressure remains. However, given Thursday’s relatively large range, natural gas could continue to consolidate at support seen near the 61.8% retracement.
A decisive drop below today’s low, also a weekly low, at $3.60, triggers a continuation of the bearish retracement. If price then continues to weaken, the next lower potential support zone around $3.48 to $3.44 becomes the next downside target. The beginning of the range is a 78.6% Fibonacci retracement of an internal upswing, while the lower boundary was resistance at the swing high in early-September. If that price zone fails to attract buyers and natural gas continues to weaken, the 78.6% Fibonacci retracement of the last full upswing becomes a potential target at $3.48.
On the upside, if a rally above $3.93 can be sustained, then potential resistance from prior support at $4.09 to the 38.2% Fibonacci retracement at $4.15 is identified as the first potential resistance zone. But the also significant 20-day average presents dynamic resistance, and it is at $4.24 currently and falling.
Natural gas remains under bearish pressure with multiple closes below the 200-day average and trendline, but the hammer off the 61.8% Fib and hold above $3.60 offers early hope for consolidation or bounce. Clearance of $3.93 targets $4.09–$4.15; failure to defend $3.60 opens $3.44–$3.48 and keeps the retracement alive.
For a look at all of today’s economic events, check out our economic calendar.
The US Court of Appeals for the Federal Circuit reversed a Trademark Trial & Appeal Board decision upholding refusal of the KAHWA mark for cafés and coffee shops, holding that the doctrine of foreign equivalents was inapplicable since KAHWA has a well-established alternative English meaning. In re Bayou Grande Coffee Roasting Co., Case No. 2024-1118 (Fed. Cir. Dec. 9, 2025) (Moore, Hughes, Stoll, JJ.)
In February 2021, Bayou applied to trademark KAHWA for cafés and coffee shops, claiming use since 2008. The examiner refused, deeming the mark generic or descriptive under the doctrine of foreign equivalents, asserting that KAHWA means “coffee” in Arabic. Bayou argued that it instead refers to a specific type of Kashmiri green tea not sold in US cafés or coffee shops. The examiner upheld refusals on both grounds and denied reconsideration.
On appeal, the Board affirmed the examiner’s refusals based on the Kashmiri green tea meaning but did not address the Arabic meaning. The Board found KAHWA generic and descriptive for cafés and coffee shops due to record evidence showing relevant customers regarded KAHWA as the generic description for a type of green tea beverage, and cafés and coffee shops serve a variety of tea beverages. Bayou appealed.
The Federal Circuit first determined that the Board’s generic and merely descriptive findings based on the Kashmiri green tea meaning did not constitute new grounds of rejection. The Court also reversed the Board’s generic and merely descriptive findings based on the Kashmiri green tea meaning.
The Federal Circuit concluded that the Board’s generic finding was not supported by substantial evidence because of undisputed evidence that no café or coffee shop in the United States sells kahwa. Therefore, whether relevant customers understood KAHWA to refer to a specific type of Kashmiri green tea was insufficient to establish genericness. The Court also held that the Board’s merely descriptive finding was not supported by substantial evidence because kahwa is neither a product/feature of café and coffee shop services nor a tea variety typically offered there. Moreover, registering KAHWA would not grant Bayou rights against cafés or coffee shops merely selling kahwa, and potential future sales were irrelevant to the descriptiveness analysis.
Finally, the Federal Circuit held that because KAHWA’s undisputed English meaning is Kashmiri green tea, translation was unnecessary, and the doctrine of foreign equivalents did not apply. Under the doctrine of foreign equivalents, a foreign mark may be translated into English to evaluate it for genericness or descriptiveness. However, translation is not required when consumers would not translate, or when the mark has a well‑established alternative meaning that makes the literal translation irrelevant.
[View source.]
XRP price today is back in the spotlight as shifting technical signals and steady trading activity renew discussion around whether the asset is approaching a short-term trend reversal.
The renewed focus follows the appearance of a TD Sequential buy signal near $1.87 on the XRP price chart, prompting analysts to reassess XRP’s near-term outlook while balancing technical indicators, liquidity conditions, and ongoing regulatory considerations.
At the time of writing on December 19, XRP is trading near $1.86, down approximately 0.55% over the past 24 hours, according to aggregated market data from major crypto exchanges. Despite the modest decline, 24-hour trading volume remains elevated at roughly $4.5 billion, reflecting sustained market participation rather than capitulation-driven selling.
XRP was trading at around 1.86, down 0.55% in the last 24 hours at press time. Source: XRP price via Brave New Coin
Earlier in the session, XRP dipped below $1.80 before rebounding nearly 4% to around $1.85, reinforcing the $1.80–$1.87 zone as a key area of interest on the XRP price chart. Although XRP remains down roughly 8% year-to-date, the ability to hold above recent lows has kept short-term reversal discussions active.
One of the main drivers behind the latest XRP price prediction discussion comes from Ali Martinez, a widely followed technical analyst known for publishing market structure analysis and indicator-based signals on X.

XRP flashes a TD Sequential buy signal, hinting at potential trend exhaustion and a possible short-term rebound. Source: @alicharts via X
“$XRP is a buy, according to the TD Sequential indicator,” Martinez wrote, highlighting the appearance of a ‘9’ buy signal on the daily timeframe near $1.87.
The TD Sequential, developed by veteran market technician Tom DeMark, is designed to identify potential trend exhaustion after a sequence of consecutive closes. In XRP’s case, the signal suggests that downside momentum may be slowing, provided the price is supported by sustained volume and follow-through buying.
Beyond momentum indicators, XRP’s broader technical structure presents a more layered picture. ChartNerd, a technical analyst who frequently publishes detailed chart breakdowns focused on liquidity and market structure, outlined XRP’s price behavior since its all-time high.

XRP may briefly sweep lower liquidity to fill October and April wicks before turning higher, as compression and momentum signals suggest a potential reversal. Source: @ChartNerdTA via X
According to the analysis, XRP has progressed through a descending triangle breakdown, an October liquidation phase, and a retest of former support-turned-resistance levels. More recently, a falling wedge pattern has emerged, alongside an upward-curving MACD and stochastic RSI compression, signaling that momentum may be building beneath the surface.
“$XRP may sweep into deeper liquidity pockets and fill in the October & April wicks,” ChartNerd noted, suggesting a potential short-term move toward the $1.50–$1.60 range before any sustained upside attempt.
This framework implies that volatility could remain elevated in the near term, even if the medium-term structure gradually improves.
Not all market observers are convinced that a trend reversal is already underway. Mrctradinglab, a TradingView analyst known for channel-based and multi-timeframe analysis, emphasized that XRP remains within a descending channel, keeping the short-term structure technically bearish.

XRP flashes a TD Sequential buy signal, hinting at potential trend exhaustion and a possible short-term rebound. Source: Mrctradinglab on TradingView
“We recently saw a reaction from daily support, but this move alone is not enough to confirm a reversal,” the analyst explained.
He noted that similar setups in the past have involved brief breakdowns below support, followed by swift recoveries. However, for bullish continuation to gain credibility, XRP would need to reclaim and hold above the broken support level, which now aligns with the upper boundary of the descending channel.
Until such confirmation appears, the current price action may represent a relief bounce within a broader downtrend, warranting close monitoring of lower timeframes for signs of a sustained reclaim.
The latest XRP price prediction reflects a market navigating an important transition zone rather than a confirmed reversal. Technical indicators such as the TD Sequential suggest that selling pressure may be easing, while momentum signals point to early stabilization. At the same time, structural resistance, liquidity risks, and broader market correlations continue to limit bullish conviction.
Analysts broadly agree that XRP’s next directional move will depend on confirmation through reclaimed resistance levels, consistent volume, and supportive market conditions. With macro uncertainty and crypto-wide volatility still present, XRP’s outlook remains conditional, reinforcing the need for measured expectations rather than premature trend assumptions.
Share this article
SolanaFloor app launched today on Solana Mobile’s dApp store, bringing real-time news and data to users of the Seeker device.
The app provides access to Solana ecosystem news, key data, curated insights, and educational content directly through the mobile platform. Seeker users can now access these features natively through the dApp store.
Solana Mobile operates a dedicated app marketplace for its Seeker smartphone, which caters to crypto users seeking mobile access to blockchain applications and services.
Silver price today is holding close to historic highs, extending a year of unusually strong momentum for the “white metal” as investors weigh a cooler U.S. inflation read against a rebounding U.S. dollar.
In early trade on Friday, December 19, spot silver was trading around $65.8–$65.9 per ounce, up modestly on the day, with the session range still brushing near the week’s peak levels. [1]
Silver’s latest move is small in percentage terms, but big in context:
The bigger headline: silver is on track for a ~6% weekly gain after printing a record high around $66.88 earlier this week, according to market reports. [5]
And 2025 has been exceptional: silver is up roughly 128% year-to-date, dramatically outperforming gold. [6]
Friday’s trading backdrop is a classic push-pull for precious metals:
1) Softer U.S. inflation supports rate-cut expectations
A lower-than-expected U.S. inflation print reinforced market expectations that the Federal Reserve could cut rates again, which tends to support non-yielding assets like precious metals. [7]
2) A firmer dollar can cap upside
At the same time, the U.S. dollar firmed near short-term highs, which can make dollar-priced commodities more expensive for non-U.S. buyers and, in turn, cool demand at the margin. [8]
This tension helps explain why silver can be “up on the day” while still struggling to extend decisively above record territory: traders are simultaneously pricing in easier policy and a currency headwind.
Silver is often described as “gold with a turbocharger”—it can rally harder, and sell off faster. What’s made 2025 different is that silver’s strength has been fed by a combination of macro drivers and market-structure catalysts.
A Reuters analysis this week highlighted three dominant supports:
In that same report, analysts pointed to how silver’s rally has been amplified by trading behavior and global participation—particularly when rising prices attract incremental speculative flows. [10]
Another recurring theme across 2025 coverage: silver’s inclusion on the U.S. critical minerals list has become a market narrative that goes beyond symbolism. Officials’ critical-minerals framework explicitly includes silver in the 2025 list, a change that market participants have linked with reshaped trade expectations and hedging against future policy/tariff risks. [11]
Reuters reporting has also connected tariff concerns to earlier flows of metal toward the U.S. and tighter liquidity dynamics in the London market at points during the year. [12]
With silver near record highs, forecasts now span a wide range—from “still room to run” to “late-stage melt-up risk.”
Several analysts cited in recent market reporting have framed $70/oz as a psychologically important next milestone:
Notably, not all institutional forecasts keep pace with the current market:
A market summary of BMO’s outlook described a scenario where BMO expects silver to peak around $60/oz in Q4 2026, with a 2026 average forecast near $56.30/oz—levels that are below today’s spot price. The same outlook also flagged overbought conditions and the possibility that supply deficits could narrow. [15]
This gap between spot and some forward averages matters: it signals that even bullish institutions may be modeling mean-reversion after a period of extraordinary upside volatility.
With silver consolidating near the highs, technical analysts are increasingly focused on whether price action is pausing for a “healthy reset” or preparing for a breakout.
Two widely followed technical takes published today point to similar zones:
One Investing.com technical note also emphasized that, after a sharp climb, silver may not move “in a straight line”—calling out stepwise upside objectives near the mid-$66s and upper-$66s while warning that pullbacks can be part of normal consolidation. [19]
Silver’s reputation for violent reversals is part of why it can outperform so dramatically on the way up. That same trait is why risk warnings tend to intensify near record highs.
A Barron’s report highlighted that silver-linked ETFs are showing extreme “stretch” versus key moving averages—conditions that research cited by the outlet suggested have historically preceded sharp pullbacks (including prior episodes where silver dropped more than 20% after similarly extended moves). [20]
Reuters has also repeatedly underscored silver’s volatility and the potential for steep corrections, even while acknowledging that supportive fundamentals (deficits, industrial demand, and investment flows) remain in play. [21]
With silver already pricing in a lot of optimism, traders are increasingly focused on catalysts that can justify either a breakout or a reset:
Silver price today remains firm near $66/oz, supported by a powerful 2025 trend and continued attention to supply tightness, industrial demand narratives, and shifting rate expectations. [26]
But with overbought warnings rising and forecasts split between “$70–$75 next” and “cooling toward ~$60 later”, the next decisive move will likely depend on whether macro conditions (the dollar, yields, and Fed expectations) turn into a tailwind—or a brake—during the final stretch of the year. [27]
1. www.kitco.com, 2. www.kitco.com, 3. www.reuters.com, 4. www.jmbullion.com, 5. www.reuters.com, 6. www.reuters.com, 7. www.reuters.com, 8. www.reuters.com, 9. www.reuters.com, 10. www.reuters.com, 11. www.federalregister.gov, 12. www.reuters.com, 13. www.reuters.com, 14. www.reuters.com, 15. news.futunn.com, 16. www.fxempire.com, 17. www.fxempire.com, 18. www.fxempire.com, 19. www.investing.com, 20. www.barrons.com, 21. www.reuters.com, 22. www.reuters.com, 23. www.reuters.com, 24. www.reuters.com, 25. www.investing.com, 26. www.kitco.com, 27. www.reuters.com
Inflammation has become somewhat of a wellness buzzword in recent years. It’s often used as a scapegoat for a myriad of vague health problems: fatigue, bloating, acne, weight gain, brain fog. The list goes on.
If you have nonspecific, persistent symptoms, or you’re just feeling off, chances are, inflammation is the culprit — at least according to social media. On TikTok, many wellness influencers frame inflammation as an unavoidable consequence of living in the modern world.
“It’s almost like a boogeyman. … Everything is from inflammation, but it can also mean nothing a lot of the times,” Dr. Zachary Mulvihill, a physician with the Integrative Health and Wellbeing Program at NewYork-Presbyterian, tells TODAY.com.
Inflammation isn’t a new concept. It was well-recognized in ancient medicine systems, Mulvihill adds.
The recent obsession rests on the idea that if you can combat inflammation, you’ll look and feel better than ever.
As a result, there’s been a boom in products marketed to fight inflammation, including supplements. In stores and online, you’ll find vitamins, minerals, herbs and other botanicals with claims to help with this nebulous health problem.
But do any of these supplements actually reduce inflammation, or is “anti-inflammatory” just another trendy label?
What is inflammation, why does it happen, and what does help lower it in the body? We spoke to experts about which popular anti-inflammatory supplements may have actual benefits.
“Generally speaking, it’s our immune system processing anything and everything,” Dr. Matthew Badgett, a primary care physician specializing in integrative medicine at the Cleveland Clinic, tells TODAY.com.
Inflammation is your body’s protective response against injury, infection and illness. Its purpose is to eliminate invaders, like bacteria, viruses, allergens and toxins, and clear out any damage so the repair process can begin, says Badgett.
The inflammatory response does this by increasing blood flow, which causes swelling, redness and heat, Dr. Natalie Azar, a rheumatologist at NYU Langone Health and NBC News medical contributor, tells TODAY.com. (Think of a red, puffy cut.)
Then the body sends out first responders — white blood cells and inflammatory cells called cytokines — which trigger the liver to produce substances called C-reactive proteins or CRP, explains Badgett. These all help the body recover and rebuild.
“Inflammation isn’t always bad,” says Azar. Acute inflammation is a sign our immune system is working. Once we’re healed, this response shuts off — usually.
Inflammation becomes problematic when it continues for too long after the body recovers or occurs in the absence of injury and illness, per the Mayo Clinic.
Chronic, low-grade inflammation can build up over time, damaging healthy tissues in nearly all parts of the body. It’s a factor in developing many diseases, says Azar, including diabetes, heart disease, rheumatoid arthritis, lupus and inflammatory bowel disease.
“Chronic inflammation is more complex,” says Azar.
The symptoms of acute inflammation are usually obvious; you can see your finger swell up after jamming, for example.
Chronic inflammation, however, is often less noticeable. “It’s super complicated,” says Mulvihill. For this reason, it’s difficult to measure, Badget adds.
There isn’t one test to measure inflammation, but doctors can check the blood for levels of inflammatory markers. “There’s a blood test for C-reactive protein. When it’s really high, we may think autoimmune diseases and infections,” says Badgett. But interpreting these results isn’t clear-cut.
Elevated CRP levels are associated with a number of diseases, but these tests aren’t diagnostic. “Why an individual’s inflammatory markers are high can be really tricky to figure out,” says Badgett.
The root cause of chronic inflammation is the immune system not shutting off its inflammatory response, which is often related to lifestyle factors. These include poor diet, lack of exercise, not sleeping, smoking tobacco, drinking alcohol and stress.
How to lower inflammation varies depending on a person’s underlying health, lifestyle and medical conditions.
“The problem with all these supplements is they have limited evidence, or … some studies show some benefit and some don’t,” says Badgett.
Because inflammation is difficult to measure, this can make it hard to study the effectiveness of specific supplements.
“I think social media and the supplement industry simplifies the message that there’s all this inflammation and you can reduce it with one supplement,” says Badgett.
There is some promising research, but it’s often condition-specific, Mulviihill notes. Here’s which popular supplements may help with chronic inflammation associated with conditions.
Fish oil has been studied for many inflammatory and autoimmune disorders, says Azar. The star nutrient is omega-3 fatty acid, known for being anti-inflammatory and protective for heart health.
“Fish oil is probably the only one that has a substantial body of evidence,” says Mulvihill.
Omega-3s may help block sources of inflammation, including pro-inflammatory cytokines, according to the Arthritis Foundation.
A 2019 meta-analysis found that omega-3 fatty acids are associated with improvements in inflammatory biomarkers in patients with diabetes and heart disease. Of 20 clinical trials involving rheumatoid arthritis, almost all found that fish oil helped reduce joint pain and swelling, says Azar.
But, “it doesn’t mean that every single person who thinks they have inflammation should just take fish oil,” says Mulvihill.
The biggest benefit is for those who have a diet lacking in fatty fish, a natural source of omega-3s. “If you’re eating fish three or four times a week, you’re unlikely to get a reduction in inflammation from fish oil,” Badgett adds.
Turmeric is a bright yellow spice that’s been used in cooking and medicine for thousands of years, says Mulvihill.
Curcumin, the biologically active compound in turmeric, is often touted for inflammation, joint pain and heart health, per the National Institutes of Health.
That’s because curcumin may help block inflammatory cytokines and enzymes, says Azar. Turmeric may lower CRP blood levels, help improve arthritis outcomes and reduce flares for people with autoimmune diseases, Badgett adds.
According to a 2021 systematic review, there’s good evidence that turmeric can help reduce the inflammatory response in patients with arthritis, IBD and psoriasis.
“But a lot of times, people over-emphasize the benefit of this one anti-inflammatory compound,” Badgett adds.
While turmeric may show promise for fighting inflammation, especially in arthritis patients, it’s also one of the riskiest supplements you can take, TODAY.com previously reported.
“Turmeric is very condition specific. A lot of people are misusing it,” says Mulvihill.
Ginger, another potent herb, is a popular for inflammation and digestive health.
There’s some evidence ginger has anti-inflammatory compounds similar to ibuprofen, and research shows it may help switch off certain inflammatory genes, says Azar.
A 2022 review of research found that ginger shows efficacy against several inflammatory diseases, and may help improve symptoms of rheumatoid arthritis, psoriasis and lupus — but more research is needed, the authors wrote.
In a double-blind randomized controlled trial of 70 Type 2 diabetes patients over three months, ginger improved insulin sensitivity and reduced CRP levels.
However, you won’t reap these anti-inflammatory benefits from ginger overnight. “If you’re really trying to reduce chronic inflammation, this is a supplement you should be taking for a long time,” says Badgett.
Vitamin D is an essential nutrient that supports strong bones, healthy immune function, and it may have anti-inflammatory properties, the experts note.
“There is some evidence that Vitamin D reduces inflammation and lowers high CRP a little bit,” says Badgett.
According to a 2024 study, vitamin D may help with the management of metabolic disorders. However, the research on vitamin D for inflammation tends to be more limited and mixed, Mulvihill adds.
Studies show a vitamin D deficiency is associated with several inflammatory diseases, but it’s unclear if the deficiency contributes to developing these diseases or it’s a symptom, according to a 2014 meta-analysis.
“If you have good vitamin D levels, I don’t think more vitamin D is going to lower your CRP or inflammation,” says Badgett.
People with conditions linked to chronic inflammation may benefit from taking fish oil, turmeric, ginger or vitamin D as directed by a health care provider.
“In the supplement world, I’d say fish oil is No. 1 and turmeric is No. 2,” Mulvihill adds.
Always talk to your doctor before starting supplements to determine which type and dosing regimen is appropriate.
“Part of it is finding the shortcomings in a patient’s diet and lifestyle that a supplement will actually help,” says Badgett.
Although supplements are often marketed as the more natural alternative to anti-inflammatory drugs like NSAIDs, they can still have a powerful impact on the body. Many cause unpleasant side effects and interact with other medications, the experts warn.
Fish oil is generally safe in moderation, says Mulvihill, but getting too much can cause excessive bleeding, per the Mayo Clinic.
Turmeric can act as a blood thinner, says Azar, and should be avoided if you take anti-coagulants or are pregnant. In high doses, turmeric can cause liver injury or failure, Mulvihill warns.
“Ginger can also interfere with medications for blood thinning, and it should not be used if you have gallstones,” says Azar.
Vitamin D is a fat-soluble vitamin, which means any excess is stored in the body. High doses can lead to vitamin D toxicity, which can cause organ failure, TODAY.com reported previously.
Lifestyle factors often fuel chronic inflammation. While supplements may fill gaps, they can’t make up for unhealthy habits.
“Eating a lot of processed, unhealthy foods, smoking cigarettes, drinking a lot of alcohol, stress are obviously very inflammatory … and those are the elephant in the room we need to address (first),” says Mulvihill.
Ultimately, the intervention with the most compelling evidence for reducing inflammation is a healthy diet.
“It’s diet where the average American has the most room for improvement, especially for inflammation,” Badgett adds.
An anti-inflammatory diet, such as the Mediterranean diet, prioritizes whole, unprocessed foods rich in nutrients that can help lower inflammation, says Mulvihill.
These include olive oil and fatty fish, such as salmon, rich sources of omega-3s. Vegetables and fruits provide plenty of vitamins, minerals, antioxidants and other anti-inflammatory plant compounds, like polyphenols, says Azar.
Whole grains and legumes are some of the healthiest carbs you can eat, and nuts and seeds are rich in healthy fats and protein.
An anti-inflammatory diet is also high in dietary fiber. Fiber intake is consistently associated with reducing inflammatory markers, says Badgett, and it helps healthy gut bacteria flourish.
Getting adequate sleep, exercising regularly and managing stress are also key steps to reducing inflammation.
“I always say, supplements are here to supplement your diet and lifestyle,” Mulvihill says.